Kornimate/medical-research-clean huggingface dataset:
performance of moto medial® unicompartmental knee arthroplasty

Conditions: Knee Osteoarthritis; Knee Arthritis; Knee Pain Chronic

Summary: this is a prospective, multi-center study, designed to assess mid-term performance of the moto medial® unicompartmental knee arthroplasty (uka), with patient report outcomes, clinical findings and radiographic analysis.

this is a prospective, multi-center study, designed to assess mid-term performance of the moto medial® uka, with patient report outcomes, clinical findings and radiographic analysis. additionally, several perioperative factors, medical and surgical history will be evaluated. implant survival and complications will be detailed throughout the study. data from pre-operative evaluation, day of surgery, and post-operatively at 4 weeks, 6 months, and years 1, 2 \& 5, will be collected.

Eligibility criteria:
inclusion criteria: * must be able to read, understand and provide written informed consent on the institutional review board (irb) approved informed consent form (icf). * ability to understand and provide written authorization for use and disclosure of personal health information. * subject who are able and willing to comply with the study protocol and follow-up visits. * must be 18 years or older to participate. * subjects must have medial knee disease in the affected knee compliant with the fda-approved indications for use of moto medial® uka. * must have had no prior arthroplasty to the medial compartment of the study knee. * subjects must be able to return for the follow-up appointments, and have the mental capacity to cooperate and complete patient reported outcome questionnaires, physical exam and radiographs. exclusion criteria: * knee ligament instability (deficiency of cruciate or collateral ligaments) * inflammatory arthritis * history of prior knee infection * history of alcoholism or drug abuse * currently on chemotherapy or radiation therapy for neoplastic disease. medacta moto medial® version 1 confidential page 9 of 36 june 5, 2017 * currently on immunosuppressive medications including steroids * history of known sensitivity or allergy to materials used in orthopedic implants, specifically titanium and cobalt-chrome alloys * habitual use of narcotic pain medications prior to surgery (more than 3 doses or pills per week) * history of metabolic disorder affecting the skeletal system other than osteoarthritis or osteoporosis (e.g., osteomalacia, ricketts) * history of chronic pain issues for reasons other than knee pain. * women who are pregnant. * psychiatric illness * any patient, in the opinion of the investigator, is unable to fully comply with the surgical, rehabilitation, or follow-up aspects of this procedure. * prior joint arthroplasty on the target knee, including prior medial uka (revision), lateral uka, or patellofemoral joint * prior high tibial osteotomy (hto).
echocardiographically guided versus standard ibuprofen treatment for patent ductus arteriosus

Conditions: Patent Ductus Arteriosus

Summary: patent ductus arteriosus (pda) is a very common condition in immature newborn babies and it has been associated to morbidity and mortality. ibuprofen is the drug of choice for pda treatment according to the last version of the cochrane review. nowadays the best dose regimen for ibuprofen remains uncertain. the investigators aim to perform a randomized controlled clinical trial to assess whether echocardiographically guided pda ibuprofen treatment versus standard treatment could reduce the number of doses of ibuprofen without increasing the reopening rate and reducing the side effects associated to this medication.

patent ductus arteriosus (pda) is presented in 55 to 70% of the preterm infants with a gestational age lower than 30 weeks or a birth weight lower than 1000 grams. pda has being associated to mortality or morbidity such as ischemic or hemorrhagic cerebral events, necrotising enterocolitis, renal disfunction or poor pulmonary outcome; however, it is not clear whether these are a consequence of the pda presence, the treatment implemented for closing it, or the immaturity of these population. pda standard treatment (st) consists on three doses of indomethacin or ibuprofen (10-5-5mg/kg) given 24 hours apart, being the surgical closure a second line therapeutic option. in spite of ibuprofen has been pointed as the drug of choice for pda treatment by the last version of the cochrane review, side effects have been associated to both medication. standard ibuprofen treatment is based on a clinical trial where the three-dose protocol seemed to be more effective than one-dose scheme for pda closure; however, the sample size was not powered to find differences statistically significant, so nowadays the best dose regimen for ibuprofen remains uncertain. functional echocardiographic assessment is spreading to all over the world. in this scenario, it has been proposed its implementation to guide pda treatment in order to individualize the number of doses of indomethacin administered as a function of patient's response, limiting the doses and side effects in those where pda presented an early constriction. the investigators hypothesized whether echocardiographically guided pda ibuprofen treatment could reduce the number of doses of ibuprofen without increasing the reopening rate and reducing the side effects associated to this medication.

Eligibility criteria:
inclusion criteria: * preterm infants with a gestational age lower than 37 weeks of gestational age * pda ≥ 1.5 mm * no contraindication to receive ibuprofen * informed consent signed. exclusion criteria: * life-threatening congenital defects * congenital heart disease * contraindication for ibuprofen administration such as oligoanuria \ 1.5 mg/dl or potential intestinal ischemia. * informed consent refused

Keywords: functional echocardiography power doppler cranial ultrasonography n-terminal probrain natriuretic peptide patent ductus arteriosus
medicinal nicotine for preventing stress induced craving and withdrawal symptoms

Conditions: Tobacco Use Disorder

Summary: the purpose of this study is to determine the timeframe (relative to a stress task) that is most effective at attenuating the increase in symptoms of tobacco craving and withdrawal that occur when smokers are presented with stressful situations.


Eligibility criteria:
inclusion criteria: * smoking an average of at least 10 cigarette per day * general good health exclusion criteria: * unstable medical or psychiatric conditions * history of severe motion sickness * women who are pregnant or breast feeding the investigators will evaluate if there are other reasons why someone may not participate
impact of turp on quality of life in patients with benign prostatic hyperplasia: a retrospective study

Conditions: Prostatic Hyperplasia; Prostatectomy; Transurethral Resection of Prostate; Quality of Life; Urinary Tract Symptoms; Treatment Outcome

Summary: this study looks at how a common surgery called turp (transurethral resection of the prostate) affects the quality of life in men with benign prostatic hyperplasia (bph), a non-cancerous enlargement of the prostate. by reviewing past medical records of patients who had this surgery, researchers will evaluate how urinary symptoms and overall well-being changed after the procedure.


Eligibility criteria:
inclusion criteria: * male patients with urinary symptoms related to prostatic obstruction * patients who underwent transurethral resection of the prostate (turp) * availability of pre- and post-operative data (including ipss) exclusion criteria: * patients with urinary symptoms not related to prostatic obstruction * patients who did not undergo turp * incomplete or missing clinical data required for analysis
evaluation of the f&p toffee nasal pillows mask, us, 2022

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this clinical investigation is to evaluate the performance and safety of the f\&p toffee nasal pillows mask in a home environment.


Eligibility criteria:
inclusion criteria: * persons who are ≥22 years of age * persons who weigh ≥66 pounds * persons who have been prescribed pap therapy by a physician * persons who are existing nasal pillows mask users with at ≥3 months of use prior to enrolment in the clinical trial * persons who are compliant with pap therapy for ≥4 hours per night for ≥70% of nights for a 14-day period within 30 days prior to enrolment in the clinical trial * persons who are fluent in spoken and written english * persons who possess the capacity to provide informed consent exclusion criteria: * persons who are intolerant to pap therapy * persons who possess, or suffer from, anatomical or physiological conditions which make pap therapy inappropriate * persons who are required to use pap therapy for \>12 hours per day or for extensive periods, not including sleep or naps * persons who are trying to get pregnant, are pregnant, or think they may be pregnant * persons who have an ipap pressure of \>25 cmh2o if on bpap * persons who use a pap therapy device for the delivery of medicines, except supplemental o2 * persons who use a pap therapy device that does not possess data recording capabilities to capture ahi and a numerical indicator of leak that is accessible to the investigation site
the analgesic effect of auditory inputs and its relation to psychological and neurobiological mechanisms

Conditions: Analgesia

Summary: the study investigates the analgesic effect of different auditory inputs. employing a within-subject design, the study includes healthy participants that are exposed to thermal stimuli while listening to three different auditory inputs. by repeating this on separate test days, the involvement of bodily processes is investigated.


Eligibility criteria:
inclusion criteria: * healthy participants with normal hearing exclusion criteria: * chronic pain conditions * other medical, psychiatric or neurological disorders * use of pain-relieving medication 24 hours prior to testing

Keywords: pain auditory inputs
pharmacokinetics and pharmacodynamics of two prolonged-release formulations of vamifeport in healthy adults

Conditions: Healthy Volunteers

Summary: this is a phase 1, single-center, randomized, open-label study to characterize the pharmacokinetics (pk), pharmacodynamics (pd), and safety of vamifeport after multiple oral administrations of one immediate-release (ir) formulation and after single and multiple oral administrations of two prolonged-release (pr) formulation in healthy adult participants.


Eligibility criteria:
inclusion criteria: * aged greater than or equal to (\>=) 18 to less than or equal to (\<=) 60 years when providing written informed consent. * healthy, as determined by the investigator based on review of defined assessments during screening. * body weight between 50 and 100 kilograms (kg) (inclusive) and body mass index within the range 18.0 to 32.0 kg per meter squared (kg/m2) (inclusive) at screening and day -1. exclusion criteria: * any clinically relevant abnormal 12-lead ecg finding at screening or day -1 (as deemed by the investigator). * serum ferritin of \ 300 ng/ml for assigned male at birth (amab) subjects or \ 300 ng/ml for assigned female at birth (afab) subjects at screening or day -1. * hemoglobin \< 13 grams per deciliter (g/dl) (8.1 millimoles per liter \[mmol/l\]) for amab subjects or 12 g/dl (7.5 mmol/l) for afab subjects at screening or day -1. * blood draw or donation of blood (\>= 450 ml) within 3 months before screening, plasma from 2 weeks before screening, or platelets from 6 weeks before screening.

Keywords: oral ferroportin inhibitor ferroportin transporter iron overload iron metabolism
brain densitometric assessment with axial computerized tomography after severe brain trauma.

Conditions: Severe Brain Trauma

Summary: processing the digital imaging and communications in medicine (dicom) of tomographic using mannheim lung analyzing software (maluna®) , to obtain volumetrical and densitometric data of brain tissue after patients with severe brain trauma

quantitative analysis of brain and structures in it, in terms of volume, weight and density, in patients with severe brain trauma, using maluna dedicated software to process dicom images. 1. st endpoint: compare these data with those obtained by ct scans analysis of patients that recur to this kind of diagnostic investigation for non-traumatic events and with negative diagnostic related to cerebral pathological implication. 2. nd endpoint: relate data obtained with clinical evaluation of the patient (cerebral physiology and outcome) 3. rd endpoint: evaluate differences in terms of volume, weight and density of brain and its structures, between patients with diffuse cerebral injury and those with localized lesions.

Eligibility criteria:
inclusion criteria: * male and female, any ethnic group * patient with severe brain trauma (gcs \< 8) * need of mechanical ventilation * clinical need of urgent ct study of brain. * need of clinical control of ct study of brain within first 72 hours from event * informed consent obtained from solicitor, due to the fact that patient is exclusion criteria: * age minor than 18 yrs old at hospitalization day * cardiac arrest pre-hospital or in-hospital and post-anoxic coma * non traumatic coma * exaggerated ingestion of depressors of central nervous system * documented abuse of narcotic drugs; * documented abuse of alcohol

Keywords: brain trauma; maluna; densitometric data ct
comparing validity of non-invasive hemoglobin monitoring to laboratory results in critically ill children

Conditions: Hemoglobin Results

Summary: this is a prospective study to determine the accuracy of the masimo pronto non-invasive hemoglobin monitor and associated rainbow® probes in the detection of hemoglobin concentration in critically ill children.

this is a prospective study to determine the accuracy of the masimo pronto non-invasive hemoglobin monitor and associated rainbow® probes in the detection of hemoglobin concentration in critically ill children. data from at least 30 patients admitted to the pediatric intensive care unit (picu) over a period of 2 months will be collected and analyzed for this study. note, that this device would not lead to deviations in routine patient care; specifically, the non-invasive monitor placed on the patient's finger is fda approved. the proposed monitors are identical macroscopically to monitors, which are currently used to measure oxygen saturation at this institution. clinical decisions, additional blood draws or alterations to the plan of care will not be made based on study data. the objective is to compare the validity of the hemoglobin values determined from non-invasive technology with measured laboratory values for hemoglobin utilized as standard of care.

Eligibility criteria:
inclusion criteria: * patient has been admitted to pediatric intensive care unit * patient age is ≥ 30 days old and ≤ 18 years old * patient weight ≥ 3 kg. * patient requires hemoglobin monitoring exclusion criteria: * patient does not have exposed fingers/toes,due to congenital anomalies wound dressing or injury. * patient weight is less than 3 kg * patient is less than 30 days old

Keywords: pediatric critically ill masimo hemoglobin monitoring unc picu
safety and efficacy of different onset times of treatment with pulsed dye laser on improvement of surgical scars

Conditions: Scar

Summary: the appearance of skin after surgery plays an important role in patient's self confidence and life style. in fact, keloids and hypertrophic scars are abnormal wound responses appearing in predisposed individuals after surgery. among different kind of lasers, used to improve the appearance of hypertrophic scars and keloids, pulsed dye laser is now being used successfully in treatment of scars. pulsed dye laser is effective in improving the color, height, texture, and elasticity of scars. also, treatment with this technique is noninvasive, minimally uncomfortable, and requires no anesthesia. this study will assess the efficacy and safety of different onset times of treatment with pulsed dye laser on improvement of surgical scars.


Eligibility criteria:
inclusion criteria: * surgical scar with minimum length of 6 cm exclusion criteria: * history of light sensitivity or photodermatoses * history of adverse reactions to laser treatment

Keywords: scar surgery lasers
closed-loop fluid administration system using hemodynamic monitors

Conditions: Intraoperative Volume Status; Postoperative Complications

Summary: the purpose of this study is to evaluate the feasibility of a closed-loop (automated) fluid administration system to deliver fluids using feedback from standard operating room hemodynamic monitors. in standard anesthesia care the rate of iv fluid administration to the patient is determined by the anesthesiologist caring for the patient. in this study protocol, the rate of fluid administration will be determined instead by the closed-loop (automated) control system under the supervision of the anesthesiologist. the system will independently decide when to give fluid and at what rate; the supervising anesthesiologist will monitor the system to ensure appropriate volumes are being delivered and to intervene if necessary.

in our protocol we will test the hypothesis that closed-loop fluid administration can maintain higher cardiac stroke volume (shown to improve patient outcomes after surgery) than anesthesiologist management. we have shown this to be the case in multiple simulation studies and in-vivo animal studies, but not yet experimentally in a clinical setting. investigators will recruit their patients from the surgical record that that require cardiac output monitoring undergoing surgery and require mechanical ventilation and consent to participate in the study will be included in the study. they will receive standard patient care in that in no way will their anesthetic or surgical procedure will be altered as part of the study, with the exception of fluid administration. fluids are usually given to a patient based on the physician's discretion. as part of the study patients will receive fluid management via a closed loop (automated) system that will use an infusion pump (q-core) and a controller (a computer run index and algorithm developed by sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors at uci). data from this study will be retrospectively compared to subjects case matched to evaluate differences in cardiac output, total fluid given, and patient outcomes.

Eligibility criteria:
inclusion criteria: * adult subjects (over the age of 18) * subjects undergoing elective major, abdominal surgery * subjects requiring general anesthesia and mechanical ventilation * subjects requiring cardiac output monitoring and an arterial line exclusion criteria: * subjects under 18 years of age * subjects not undergoing surgery * subjects not requiring general anesthesia or mechanical ventilation * subjects not requiring cardiac output monitoring or an arterial line * subjects who are pregnant * subjects without the capacity to give informed consent
randomized controlled trials on clinical outcomes of totally laparoscopic versus laparoscopy assisted total gastrectomy for gastric cancer

Conditions: Stomach Neoplasms

Summary: the purpose of this study is to explore clinical outcomes of totally laparoscopic versus laparoscopy assisted total gastrectomy for gastric cancer.


Eligibility criteria:
inclusion criteria: 1. age between 18 to 75 years old 2. primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy 3. locally advanced tumor in the middle third stomach（ct1-4a, n-/+, m0 at preoperative evaluation according to the ajcc(american joint committee on cancer) cancer staging manual seventh edition） 4. no distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in the preoperative examinations 5. performance status of 0 or 1 on ecog (eastern cooperative oncology group) scale 6. asa (american society of anesthesiology) class i to iii 7. written informed consent exclusion criteria: 1. pregnant and lactating women 2. suffering from severe mental disorder 3. history of previous upper abdominal surgery (except for laparoscopic cholecystectomy) 4. history of previous gastric surgery (including esd/emr (endoscopic submucosal dissection/endoscopic mucosal resection )for gastric cancer) 5. enlarged or bulky regional lymph node （diameter over 3cm）supported by preoperative imaging including enlarged or bulky no.10 lymph node 6. history of other malignant disease within the past 5 years 7. history of previous neoadjuvant chemotherapy or radiotherapy 8. history of unstable angina or myocardial infarction within the past 6 months 9. history of cerebrovascular accident within the past 6 months 10. history of continuous systematic administration of corticosteroids within 1 month 11. requirement of simultaneous surgery for other disease 12. emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer 13. fev1\<50% of the predicted values

Keywords: stomach neoplasms totally laparoscopic total gastrectomy laparoscopy assisted total gastrectomy
osteoarthritis care tools for primary care providers

Conditions: Arthritis; Osteo Arthritis Knee

Summary: the purpose of this pilot study is to test oacaretools+, an intervention for healthcare providers that combines education, patient resources and support from a national organization, to help them make referrals of patients with arthritis to the walk with ease program. this intervention was designed to increase referrals of patients with arthritis to the walk with ease program.

participants will be clinicians (n= 50) in a primary care practice and a subset of patients (n=10). the study team will deliver education and resources to providers in a training session about walk with ease. after the provider training, providers will use the study resources to refer patients with arthritis to walk with ease. healthcare provider participants will complete surveys after their first referral and at the end of the study (12-months). patient participants who are referred to walk with ease through the oacaretools+ intervention will participate in interviews about their experience (6-weeks) with the referral process. primary endpoints of the study will be 1) number of healthcare providers that referred patients to walk with ease 2) number of walk with ease patient participants 3) healthcare provider acceptability and feasibility 4) patient acceptability of the intervention.

Eligibility criteria:
inclusion criteria: * healthcare provider participants: currently a healthcare provider or staff person in the unc pilot clinic * patient participants: 18 years or older; received a referral to walk with ease from a provider at the unc pilot clinic; agreed to participate in the phone interview on the post-walk with ease evaluation form exclusion criteria: * both: non-english speaking

Keywords: healthcare providers arthritis primary care